Current Drug Scheduling Reviews Reported by DEA
The FASEB Journal April 1, 2009 Sandy Ghozland, Srihari R. Tella, Michelle D. Walker et al.
The DEA collects and reviews scientific, medical, and other data on substances with abuse potential to determine whether they should be placed under the Controlled Substances Act (CSA). Ongoing scheduling processes involve indiplon, carisoprodol, dextromethorphan, salvinorin A, and several petitions regarding nabilone, methylphenidate, marijuana and tetrahydrocannabinols, tramadol, anabolic steroids, and sibutramine. Many hallucinogens, including 5-MeO-DMT, 5-MeO-AMT, 5-MeO-DET, 5-MeO-MIPT, DIPT, 4-OH-DIPT, 2C-I, 2C-T-2, and Bromo-dragonfly, are under review for possible control. Chemical and pharmacological studies for DOC, 2C-C, 2C-D, and 2C-E are ongoing. Additionally, to comply with the 1971 Convention on Psychotropic Substances, DEA is reviewing zipeprol, amineptine, mesocarb, 4-MTA, and brotizolam for control under the CSA.